Mirum Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
14analysts covering
FY Revenue (est.)
$696.6Mnext fiscal year
FY EPS (est.)
-$15.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Global Net Product Sales Annually521.3MTarget: 660000000 to 680000000
LIVMARLI Net Product Sales Quarterly113.8M
Bile Acid Medicines Net Product Sales Quarterly46.1M
Watch Items
- Zilurgisertib FDA PDUFA DateAction: Monitor FDA decision on approval for fibrodysplasia ossificans progressiva (FOP).
- Volixibat NDA Submission in PSCTrigger: Second Half of 2026Action: Track submission of the New Drug Application to the FDA following positive Phase 2b VISTAS results.
- Brelovitug Phase 3 AZURE-1 and AZURE-4 Topline ResultsTrigger: Second Half of 2026Action: Evaluate clinical efficacy and safety data in chronic hepatitis delta virus (HDV) to support planned 2027 regulatory filings.
- LIVMARLI EXPAND Phase 3 Topline DataTrigger: Fourth Quarter of 2026Action: Review clinical data for pruritus in additional rare cholestatic conditions to support label expansion.
Research as of 19 Jun 2026